Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia-Reference-Cited by-同舟云学术

Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia

Published:2018-12 Issue: Volume:17 Page:21-31
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Lara Carlos,De Graeve Diana,Franco Fabian

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference72 articles.

1. World Health Organization Pneumonia. 2016. Available from: http://www.who.int/mediacentre/factsheets/fs331/en/. [Accessed February 17, 2018].

2. Insights into the interaction between influenza virus and pneumococcus;McCullers;Clin Microbiol Rev,2006

3. World Health Organization. Pneumococcal vaccines WHO position paper-2012. Weekly Epidemiological Record. 2012. Available from: http://www.who.int/wer/2012/wer8714.pdf. [Accessed February 17, 2018].

4. World Health Organization. Pneumococcal disease. 2013. Available from: http://www.who.int/immunization/topics/pneumococcal_disease/en/. [Accessed February 17, 2018].

5. World Health Organization. Vaccines against influenza WHO position paper-November 2012. 2012. Available from: http://www.who.int/wer/2012/wer8747.pdf. [Accessed February 17, 2018].

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022;PLOS Medicine;2024-01-05

2. Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2021;2023-05-08

3. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine compared to the 10-valent vaccine in children: predictive analysis in the Ecuadorian context;Journal of Pharmaceutical Health Services Research;2022-10-18

4. Return on Investment of 10-Valent Pneumococcal Conjugate Vaccine in Ecuador From 2010 to 2030;Value in Health Regional Issues;2022-09

5. Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses;PharmacoEconomics - Open;2021-05-04